TY - JOUR
T1 - Combinations of 5-FU, hypoxanthine, and allopurinol in chemotherapy for human colon adenocarcinoma xenografts
AU - Houghton, J. A.
AU - Houghton, P. J.
PY - 1982
Y1 - 1982
N2 - A series of four human colon adenocarcinomas, growing as xenografts in immune-deprived mice, have been used to evaluate the efficacy of 5-FU in combination with two purines, hypoxanthine (Hx) and allopurinol (HPP), which have reduced the toxicity of 5-FU in host mice. Tumor-bearing mice were treated at 7-day intervals with 5-FU administered simultaneously with the protecting agents (Hx and HPP). Two tumor lines (HxVRC5 and HxGC3), insensitive to 5-FU alone, failed to show any response to this combination. In 5-FU-sensitive HxELC2 tumors, the combination of 5-FU with Hx and HPP did not increase the therapeutic index, and in HxHC1 xenografts, antagonism to 5-FU cytotoxicity was observed. Tumor response in relation to the pathways of 5-FU metabolism is discussed.
AB - A series of four human colon adenocarcinomas, growing as xenografts in immune-deprived mice, have been used to evaluate the efficacy of 5-FU in combination with two purines, hypoxanthine (Hx) and allopurinol (HPP), which have reduced the toxicity of 5-FU in host mice. Tumor-bearing mice were treated at 7-day intervals with 5-FU administered simultaneously with the protecting agents (Hx and HPP). Two tumor lines (HxVRC5 and HxGC3), insensitive to 5-FU alone, failed to show any response to this combination. In 5-FU-sensitive HxELC2 tumors, the combination of 5-FU with Hx and HPP did not increase the therapeutic index, and in HxHC1 xenografts, antagonism to 5-FU cytotoxicity was observed. Tumor response in relation to the pathways of 5-FU metabolism is discussed.
UR - http://www.scopus.com/inward/record.url?scp=0019967231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019967231&partnerID=8YFLogxK
M3 - Article
C2 - 7083222
AN - SCOPUS:0019967231
SN - 0361-5960
VL - 66
SP - 1201
EP - 1206
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
IS - 5
ER -